Immunotherapy for early triple negative breast cancer: research agenda for the next decade
出版年份 2022 全文链接
标题
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
作者
关键词
-
出版物
npj Breast Cancer
Volume 8, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-02-18
DOI
10.1038/s41523-022-00386-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
- (2021) Thomas Bachelot et al. NATURE MEDICINE
- Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials
- (2021) Paolo Tarantino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
- (2021) Larissa A. Korde et al. JOURNAL OF CLINICAL ONCOLOGY
- The Global Landscape of Treatment Standards for Breast Cancer
- (2021) Dario Trapani et al. JNCI-Journal of the National Cancer Institute
- Tumor mutational burden as a predictor of immunotherapy response in breast cancer
- (2021) Tess A. O’Meara et al. Oncotarget
- Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
- (2021) Karthik Dhatchinamoorthy et al. Frontiers in Immunology
- Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials
- (2021) Sonia L. Villegas et al. EUROPEAN JOURNAL OF CANCER
- Breast cancer
- (2021) Sibylle Loibl et al. LANCET
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- How to use liquid biopsies to treat patients with cancer
- (2021) L. De Mattos-Arruda et al. ESMO Open
- VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
- (2021) P. Schmid et al. ANNALS OF ONCOLOGY
- Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort
- (2021) S. Schrodi et al. ANNALS OF ONCOLOGY
- Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
- (2021) Paula I. Gonzalez-Ericsson et al. CLINICAL CANCER RESEARCH
- Managing side effects of immune checkpoint inhibitors in breast cancer
- (2021) Carmen Criscitiello et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- It Is Time to Talk About Fertility and Immunotherapy
- (2020) Narjust Duma et al. ONCOLOGIST
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer
- (2020) Carolyn Cullinane et al. JAMA Network Open
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
- (2020) M.J.M. Magbanua et al. ANNALS OF ONCOLOGY
- Circulating tumor DNA analysis in breast cancer: is it ready for prime-time?
- (2019) Giuseppe Buono et al. CANCER TREATMENT REVIEWS
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
- (2019) Richard Gray et al. LANCET
- Defining the immunogram of breast cancer: a focus on clinical trials
- (2019) Paolo Tarantino et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
- (2019) Katherine E. Hutchinson et al. CLINICAL CANCER RESEARCH
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
- (2019) J H Park et al. ANNALS OF ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Immunological differences between primary and metastatic breast cancer
- (2018) B Szekely et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started